Progressive multifocal leukoencephalopathy following rituximab treatment

Community Oncology

Volumn 6, Issue 9, 2009, Pages 410-411

  Frick, Melissa ^a   Maloney, Caitlin ^a   Tallman, Samuel ^a   Samaras, Athena T ^a,b   McKoy, June M ^a   Bennett, Charles L ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

AUTOIMMUNE DISEASE; CLINICAL FEATURE; DRUG FATALITY; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; IDIOPATHIC AUTOIMMUNE PANCYTOPENIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; JC VIRUS; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RHEUMATOID ARTHRITIS; RISK FACTOR; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS REACTIVATION;

EID: 70350459427     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70270-4     Document Type: Short Survey

References (3)

1. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;20:4824-4840.
2. Scott SD. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract 1998;6:195-197. (Pubitemid 28225643)
3. FDA. Information for Healthcare Professionals. Rituximab (marked as Rituxan). FDA Alert: Information for Healthcare Professionals. Rockville, MD, December 2006. www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm126518.pdf. Accessed August 31, 2009.